
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BORIS CRISPR/Cas9 KO Plasmid (h2) | sc-403313-KO-2 | 20 µg | $397.00 | |||
BORIS HDR Plasmid (h2) | sc-403313-HDR-2 | 20 µg | $445.00 |
CTCFL encodes BORIS (Brother of the Regulator of Imprinted Sites), a cancer-testis transcription factor paralogous to CTCF that binds DNA through conserved zinc finger domains and reshapes chromatin organization. BORIS participates in transcriptional control, epigenetic reprogramming, and regulation of genome architecture, influencing processes such as promoter/enhancer activity, germline gene expression, and DNA methylation-dependent silencing. Aberrant BORIS expression has been linked to dysregulated gene networks in multiple tumor contexts, where it is associated with altered chromatin states, genomic instability, and activation of normally restricted germline programs. These properties make CTCFL a useful target for investigating mechanisms of transcriptional insulation, imprinting-related regulation, and oncogenic epigenetic remodeling in human cells.
BORIS CRISPR/Cas9 KO Plasmid (h2) is a pool of plasmids designed for targeted disruption of the CTCFL gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the CTCFL locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, BORIS HDR Plasmid (h2) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined CTCFL target site.
When co-transfected with BORIS CRISPR/Cas9 KO Plasmid (h2):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the CTCFL locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.